Suppr超能文献

在顺铂诱导的大鼠肾损伤模型中,用于测量尿液生物标志物的MesoScale Discovery和Luminex多重检测平台的比较。

Comparison of the MesoScale Discovery and Luminex multiplex platforms for measurement of urinary biomarkers in a cisplatin rat kidney injury model.

作者信息

Pavkovic Mira, Riefke Björn, Gutberlet Katrin, Raschke Marian, Ellinger-Ziegelbauer Heidrun

机构信息

Investigational Toxicology, GDD-GED-Tox, Bayer Pharma AG, 42096 Wuppertal, Germany.

Investigational Toxicology, GDD-GED-Tox, Bayer Pharma AG, 13353 Berlin, Germany.

出版信息

J Pharmacol Toxicol Methods. 2014 Mar-Apr;69(2):196-204. doi: 10.1016/j.vascn.2013.11.003. Epub 2013 Dec 12.

Abstract

INTRODUCTION

In the past years several new urinary nephrotoxicity biomarkers have been qualified for use in preclinical studies by the FDA and EMA. Subsequently, kits have been developed to measure these urinary biomarkers on multiplex platforms such as the electro-chemiluminescent based immunoassay from MesoScale Discovery (MSD) and the bead-based immunoassay using Luminex xMAP technology (LMX). The aim of the present study was to compare the two multiplex platforms with respect to the capability of their qualified urinary biomarker panels to measure an increase of these biomarkers relative to histopathological changes in an animal model of nephrotoxicity.

METHODS

For comparison of the two platforms we used urine samples from a study with the well-characterized nephrotoxin cisplatin (Cp) in male Wistar rats. The following five biomarkers were measured on both platforms: glutathione S-transferase α (αGST), clusterin (CLU), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL, a.k.a. lipocalin-2) and osteopontin (OPN). The measurements were compared with respect to both the fold increase observed for each biomarker and the absolute concentrations measured in relation to traditional endpoints for nephrotoxicity in clinical pathology and histopathology.

RESULTS

The platform comparison revealed the expected increases of urinary biomarkers after Cp treatment with similar results at the fold change level enabling consistent detection of kidney injury. The comparison of the absolute concentrations of biomarkers measured in the two platforms showed differences, the extent of which was analyte-dependent.

DISCUSSION

By comparison of two widely used multiplex platforms, MSD and LMX, for the detection of renal toxicity biomarkers in urine, we observed the expected increases of these biomarkers in response to Cp administration. Depending on the marker, significant differences could be found when comparing the absolute concentrations thus suggesting that baseline levels for each platform will have to be set separately.

摘要

引言

在过去几年中,美国食品药品监督管理局(FDA)和欧洲药品管理局(EMA)已批准几种新的尿肾毒性生物标志物用于临床前研究。随后,人们开发了试剂盒,以在多种平台上测量这些尿生物标志物,如MesoScale Discovery(MSD)基于电化学发光的免疫测定法和使用Luminex xMAP技术(LMX)的基于微球的免疫测定法。本研究的目的是比较这两种多种平台在其合格的尿生物标志物检测组测量这些生物标志物相对于肾毒性动物模型中组织病理学变化的增加情况的能力。

方法

为了比较这两种平台,我们使用了一项关于雄性Wistar大鼠中特征明确的肾毒素顺铂(Cp)的研究中的尿液样本。在两个平台上都测量了以下五种生物标志物:谷胱甘肽S-转移酶α(αGST)、簇集素(CLU)、肾损伤分子-1(KIM-1)、中性粒细胞明胶酶相关脂质运载蛋白(NGAL,又名脂质运载蛋白-2)和骨桥蛋白(OPN)。就每种生物标志物观察到的增加倍数以及相对于临床病理学和组织病理学中肾毒性传统终点测量的绝对浓度而言,对测量结果进行了比较。

结果

平台比较显示,Cp治疗后尿生物标志物预期增加,在倍数变化水平上结果相似,能够一致地检测到肾损伤。两个平台上测量的生物标志物绝对浓度的比较显示出差异,差异程度取决于分析物。

讨论

通过比较两种广泛使用的用于检测尿液中肾毒性生物标志物的多种平台,即MSD和LMX,我们观察到这些生物标志物在给予Cp后预期的增加。根据标志物的不同,比较绝对浓度时可能会发现显著差异,因此表明每个平台的基线水平必须单独设定。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验